Tagged with S

Erowlabs You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at Erowlabs, what were the main challenges you faced in order to establish the company in Brazil’s extremely competitive generics market?…

Ipsen Ukraine Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian operations of Ipsen been faring in comparison to the global performance of the company? Let me first provide you a…

Sanofi SA Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The healthcare market has seen a major shift in the way the pharmaceutical sector and the South African government engage with…

Astellas Ukraine Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi and then later as Astellas once the merger was complete. Since then, the company has been quite active with a…

Pharma Dynamics In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new dimension has Pharma Dynamics today in the South African pharma market, and how have you integrated the company’s growth in…

IMS Health South Africa Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio? For us, like many other multinationals (MNCs), South Africa remains a vibrant growth market. It is a country that we…

IMS Health South Africa Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not a commodity generics market. The brand is important in South Africa and a lot of our generics are not International…

AstraZeneca Russia You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in Kaluga. What are the implications of this project for AstraZeneca and why was it important for you to invest here?…

Sandoz Hungary Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players… you are in charge of a second association for generic players. Can you first explain why the need for this…

Lorenz Life Science Group In 2010, South Africa officially joined the BRICS grouping. The Indian and Russian work environments are familiar to you, considering your significant experience in these countries. How would you compare South Africa with its BRIC counterparts in terms of its regulatory environment? It has been eight months since I first…

IMS Health Hungary IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from the other markets in the region? I believe none of the countries of the region is having a good time…

IMSA - Innovative Medecine South Africa Ms Beaumont, can you describe the association to our readers and its main objectives? Innovative Medicines South Africa (IMSA) represents manufacturers of research-based medicines, ie they market the products of their own research. Many of our members do have generic medicines in their product portfolio, and we believe there is…